Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors.
Publication/Presentation Date
5-5-2018
Abstract
Chimeric antigen receptor (CAR) T cell therapy is a novel and innovative immunotherapy. CAR-T cells are genetically engineered T cells, carrying MHC independent specific antigen receptor and co-stimulatory molecule which can activate an immune response to a cancer specific antigen. This therapy showed great results in hematological malignancies but were unable to prove their worth in solid tumors. Likely reasons for their failure are lack of antigens, poor trafficking, and hostile tumor microenvironment. Excessive amount of research is going on to improve the efficacy of CAR T cell therapy in solid tumors. In this article, we will discuss the challenges faced in improving the outcome of CAR T cell therapy in solid tumors and various strategies adopted to curb them.
Volume
35
Issue
6
First Page
87
Last Page
87
ISSN
1559-131X
Published In/Presented At
Jindal, V., Arora, E., & Gupta, S. (2018). Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors. Medical oncology (Northwood, London, England), 35(6), 87. https://doi.org/10.1007/s12032-018-1149-9
Disciplines
Medicine and Health Sciences
PubMedID
29730801
Department(s)
Department of Obstetrics and Gynecology
Document Type
Article